Health
Question mark over effectiveness of Pfizer-BioNTech COVID-19 vaccine in obese people – BioPharma-Reporter.com
New data may have serious implications for the development of vaccination strategies for COVID-19, particularly in individuals with obesity.
A study by a team of researchers based at Istituti Fisioterapici Ospitalieri (IFO) in Rome, Italy, aimed to analyse the antibody response following two doses of the Pfizer/BioNTech COVID-19 vaccine, BNT162B2, in 248 healthcare workers. They also looked to evaluate how the antibody titer in those participants changed in relation to age, gender and body mass index (BMI).
Of the cohort studied, 158 were women (63.7%) and 90 were men (36.3%). The average age was 47 years, with the range going from 23…
-
Noosa News21 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News24 hours agoFrom Dreamy Dining Rooms to Moody Basement Bars, Nearly 200 Venues Have Been Shortlisted for the 2025 Australian Interior Design Awards
-
Noosa News21 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General20 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off